Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.696
EU - Europa 4.184
AS - Asia 2.693
SA - Sud America 340
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 9
Totale 16.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.497
HK - Hong Kong 846
RU - Federazione Russa 761
IT - Italia 724
SG - Singapore 706
CN - Cina 667
SE - Svezia 513
UA - Ucraina 505
IE - Irlanda 473
DE - Germania 471
BR - Brasile 296
GB - Regno Unito 202
CA - Canada 176
VN - Vietnam 144
FI - Finlandia 140
AT - Austria 128
FR - Francia 85
KR - Corea 76
IN - India 59
DK - Danimarca 45
NL - Olanda 42
TR - Turchia 39
ID - Indonesia 26
JP - Giappone 23
BE - Belgio 21
BD - Bangladesh 20
PL - Polonia 20
ZA - Sudafrica 18
MX - Messico 16
ES - Italia 14
IQ - Iraq 14
IR - Iran 13
AR - Argentina 12
PK - Pakistan 12
EC - Ecuador 10
EU - Europa 9
VE - Venezuela 9
AU - Australia 8
AL - Albania 7
MA - Marocco 7
IL - Israele 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
PH - Filippine 5
RO - Romania 5
TW - Taiwan 5
UY - Uruguay 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
CO - Colombia 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
LT - Lituania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
GR - Grecia 2
MK - Macedonia 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
SC - Seychelles 2
TH - Thailandia 2
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
LV - Lettonia 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SN - Senegal 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 16.971
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.845
Woodbridge 1.187
Hong Kong 834
Fairfield 676
Houston 666
Jacksonville 521
Ashburn 508
Singapore 466
Dublin 440
Chandler 414
Wilmington 399
Dearborn 335
Seattle 298
Frankfurt am Main 279
Cambridge 255
Princeton 218
New York 217
Santa Clara 181
Milan 172
Vienna 118
Altamura 106
Lawrence 104
Nanjing 104
Lachine 91
Shanghai 81
Beijing 77
Moscow 75
Seoul 65
Fremont 49
Andover 46
Boardman 46
Los Angeles 45
San Diego 43
Helsinki 38
Nanchang 37
Ottawa 37
Guangzhou 36
Hebei 34
Munich 33
Toronto 31
Rome 30
Jiaxing 28
Shenyang 27
Council Bluffs 25
Jakarta 25
London 24
Changsha 23
Hefei 23
São Paulo 23
Huizen 22
Chicago 21
Dallas 21
Tianjin 21
Brussels 20
Falls Church 19
Hanoi 19
Ho Chi Minh City 19
Kunming 18
Norwalk 18
Lissone 17
Detroit 16
Pune 16
Rio de Janeiro 16
Dong Ket 14
Hangzhou 14
Bologna 13
Mountain View 13
Nuremberg 13
Düsseldorf 12
Shenzhen 12
Warsaw 12
Columbus 11
Florence 10
Monza 10
Jinan 9
Tokyo 9
University Park 9
Ankara 8
Auburn Hills 8
Redmond 8
The Dalles 8
Zhengzhou 8
Brooklyn 7
Edmonton 7
Lanzhou 7
Leawood 7
Naples 7
Secaucus 7
Tirana 7
Turku 7
Belo Horizonte 6
Campinas 6
Desio 6
Kent 6
Kiev 6
Palermo 6
Quito 6
Sacramento 6
San Francisco 6
San Mateo 6
Totale 12.015
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 519
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 413
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 325
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 306
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 291
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 291
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 262
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 250
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 248
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 237
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 217
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 217
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 211
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 208
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 202
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 196
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 190
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 189
Uterine leiomyosarcoma: analysis of treatment failures and survival 186
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 185
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 184
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 182
Synchronous early-stage endometrial and ovarian cancer 180
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 180
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 178
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 177
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 172
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 169
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 164
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 164
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 163
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 163
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 161
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 160
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 159
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 159
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 157
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 156
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 153
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 153
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 153
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 152
Endometrial stromal sarcoma: analysis of treatment failures and survival 152
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 151
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 151
Optimal treatment of early-stage ovarian cancer 151
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 150
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 150
Antiemetic efficacy of granisetron in patients with gynecological malignancies 149
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 148
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 148
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 147
Color Doppler ultrasound in the preoperative assessment of adnexal masses 145
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 144
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 143
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 143
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 143
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 141
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 141
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 139
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 137
Clinically oriented three-step strategy to the assessment of adnexal pathology 135
Endometriomas: Their ultrasound characteristics 134
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 132
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 131
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 129
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 129
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 128
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 128
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 127
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 125
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 125
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 122
Alpha-fetoprotein in the management of germ cell tumors of the ovary 122
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 122
Ifosfamide in the treatment of malignant epithelial ovarian tumors 121
Second-look laparotomy in the management of fallopian tube carcinoma 120
Brain metastases from endometrial carcinoma 120
Tumor volume as risk factor for nodal diffusion in endometrial cancer 117
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 115
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 115
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 114
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 113
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 112
Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can reliably classify them as benign or malignant before surgery? 112
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis 110
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 109
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 107
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 105
ΔNp63 expression is associated with poor survival in ovarian cancer 104
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 102
Neoplasie dell’apparato genitale femminile 100
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 99
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel 98
Fertility outcomes in stage I ovarian immature teratomas 97
Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases 96
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 94
Fertility-sparing surgery in uterine leiomyosarcoma 93
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 92
Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery 92
Totale 16.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.887 124 82 178 186 122 153 192 179 195 208 109 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/2026659 659 0 0 0 0 0 0 0 0 0 0 0
Totale 17.369